Drug intelligence / Profile preview

Limtop

Development stage: Unknown
Lead developer: Moberg Pharma
Modality: Small Molecules
Administration: Topical

Overview

**Limtop** is an innovative topical formulation of imiquimod, a toll-like receptor 7 (TLR7) agonist, developed by Moberg Derma for dermatological conditions. Imiquimod stimulates innate immune responses by activating plasmacytoid dendritic cells to produce interferon-alpha and other cytokines, leading to antiviral, antiproliferative, and antitumor effects. It is being investigated primarily for actinic keratosis, genital warts, and basal cell carcinoma, aiming to improve upon standard cream formulations with better tolerability, efficacy, or application properties.

Brand names: Limtop

Targets

TLR7 (Toll-like receptor 7)

Beyond the preview

Go deeper on Limtop.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Limtop.

Explore the full profile